Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population

NCT03213080 is registered in ClinicalTrials.gov with Nuvaira, Inc. as lead sponsor.

NCT NCT03213080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population
Lead sponsor
Nuvaira, Inc.
Phase
Observational
Overall status
Withdrawn
Start date
December 31, 2017
Completion date
September 30, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

copd